This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Mitral-Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation
251 pts with severe ischemic MR were randomized to MV repair or chordal-sparing MV replacement. The end point was LVESVI at 12 mos. LVESVI and mortality were similar between the groups at follow-up. Recurrent MR was more common in the repair group (32.6% vs 2.3%). Other outcomes including major adverse events and QOL were similar between the groups.